Compare UTZ & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTZ | ARVN |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 912.7M | 781.0M |
| IPO Year | 2018 | 2018 |
| Metric | UTZ | ARVN |
|---|---|---|
| Price | $8.25 | $13.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 21 |
| Target Price | $13.00 | ★ $15.71 |
| AVG Volume (30 Days) | ★ 1.8M | 749.6K |
| Earning Date | 05-11-2026 | 05-27-2026 |
| Dividend Yield | ★ 3.00% | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $1,438,800,000.00 | $262,600,000.00 |
| Revenue This Year | $4.95 | N/A |
| Revenue Next Year | $1.59 | N/A |
| P/E Ratio | $857.50 | ★ N/A |
| Revenue Growth | ★ 2.09 | N/A |
| 52 Week Low | $8.37 | $5.90 |
| 52 Week High | $14.67 | $14.22 |
| Indicator | UTZ | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 29.25 | 55.83 |
| Support Level | N/A | $11.07 |
| Resistance Level | $10.74 | $13.97 |
| Average True Range (ATR) | 0.30 | 0.76 |
| MACD | -0.10 | 0.09 |
| Stochastic Oscillator | 7.64 | 80.54 |
Utz Brands Inc is a manufacturer of branded salty snacks. It produces a broad offering of salty snacks, including potato chips, tortilla chips, pretzels, cheese snacks, pork skins, pub/party mixes, and other snacks. Its iconic portfolio of authentic, craft, and better-for-you (BFY) brands, which includes Utz, Zapp's, On The Border, Golden Flake, and Boulder Canyon, among others, enjoys household penetration in the United States, where its products can be found in approximately half of U.S. household. The company operates in eight manufacturing facilities with a broad range of capabilities, and its products are distributed nationally to grocery, mass, club, convenience, drug, e-commerce and other retailers through direct shipments, distributors, and approximately 2,500 DSD routes.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.